A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal Carcinoma. (SHOGUN Trial)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Determine the Recommended dose (RD)
Based on the incidence of dose-limited toxicities(DLT), the RD is determined from 4 test levels
10 weeks
Yes
Toshiaki Watanabe, M.D.
Principal Investigator
Tokyo University
Japan: Ministry of Health, Labor and Welfare
JACCRO CC-04
NCT01227239
September 2010
August 2016
Name | Location |
---|